PG
CRMD icon

PEAK6 Group’s CorMedix CRMD Stock Holding History

PEAK6 Group’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-6,800
Closed -$68K – 4823
2015
Q3 		$68K Sell
6,800
-25,600
-79% -$395K ﹤0.01% 4529
2015
Q2 		$629K Buy
32,400
+9,060
+39% +$311K ﹤0.01% 2524
2015
Q1 		$1.15M Buy
+23,340
New +$553K 0.01% 1753

Other funds holding CRMD

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PEAK6 Group's CRMD Position: Q4 2015 in Review

PEAK6 Group sold out of CorMedix (CRMD) in Q4 2015, closing a stake of 8,000 shares — an estimated $80K sold.

PEAK6 Group first reported a position in CRMD in Q1 2015 and held it in 3 quarters. The position peaked at $698K in Q2 2015. 52 funds tracked by Wall St. Rank hold CRMD as of Q4 2015.

  • PEAK6 Group reported no remaining CorMedix position as of Q4 2015 after selling out during the quarter.
  • PEAK6 Group sold 8,000 CorMedix shares in Q4 2015, an estimated $80K.
  • PEAK6 Group first reported a position in CorMedix in Q1 2015 and held it in 3 quarters.
  • PEAK6 Group's CorMedix position peaked at $698K in Q2 2015.
  • 52 funds tracked by Wall St. Rank held CorMedix as of Q4 2015.

Based on PEAK6 Group's 13F filing for Q4 2015, filed 16 Feb 2016.